Compare Mondaycom Ltd (MNDY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? Mondaycom Ltd trades at $87.16 (market cap $3.70B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MNDY | TVTX | |
|---|---|---|
Market Cap | $3.70B | $5.02B |
Volume | 948,435 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $205.24 | $67.52 |
52-Week Low | $58.81 | $26.79 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $2.87B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $84.69, down 0.08% on the day, with technical indicators showing a neutral bias amid mixed moving average signals. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.48 versus $1.11 expected, and maintains robust profitability with an 88.74% gross margin. Recent news highlights inclusion in growth stock lists and AI-focused developments at the upcoming Elevate '26 conference.
The stock presents a compelling growth opportunity with a consensus price target of $108.64, implying 28% upside, supported by bullish analyst sentiment (61.5% buy ratings). Key risks include elevated valuation multiples (P/E 37.13) and competitive pressures in enterprise software. Positive cash flow generation and enterprise client growth momentum underpin the investment case, though investors should monitor execution on AI initiatives and margin sustainability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
